Testing a new drug combination before prostate cancer surgery
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug (BMS-986365) combined with another hormone therapy (degarelix) before radical prostatectomy for high-risk prostate cancer. The goal is to see if this combination helps lower cancer activity before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have high-risk prostate cancer that has not spread beyond the pelvis.
- You must be a candidate for radical prostatectomy (surgery to remove the prostate).
- You must have good organ function, including kidney, liver, and blood cell counts.
- You cannot have had prior chemotherapy, immunotherapy, or radiation for prostate cancer.
- You must not have significant heart disease, uncontrolled high blood pressure, or a history of certain heart rhythm problems.
- You must agree to use condoms during sexual activity while on the study and for at least 2 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of hormone therapy, a targeted pill (Darolutamide), and an immunotherapy drug (Pembrolizumab) before and after surgery for men with high-risk prostate cancer that has specific genetic features. The goal is to see if this approach helps prevent the cancer from coming back.
This trial tests a combination of a targeted radioactive drug (177Lu-PSMA-617) and a hormone blocker (Darolutamide) given before surgery for high-risk prostate cancer that hasn't spread. The goal is to see if this approach can improve outcomes.
This trial tests whether giving hormone therapy (androgen deprivation therapy) before surgery can improve outcomes for men with high-risk prostate cancer. You will receive a special PSMA PET/CT scan to see how the cancer responds.
This trial tests whether combining four drugs (chemotherapy, hormone therapy, and a new medicine) before surgery can help men with aggressive prostate cancer. The goal is to shrink tumors and improve outcomes before the prostate is surgically removed.
This trial tests a combination of darolutamide (a hormone-blocking pill) and standard hormone therapy (ADT) given before prostate surgery. It is for men with high-risk prostate cancer that has not spread to distant parts of the body, to see if the treatment can improve outcomes.
This trial tests giving a new hormone-blocking drug (darolutamide) plus standard hormone therapy before surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach improves outcomes.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.